0001209191-22-062044.txt : 20221219 0001209191-22-062044.hdr.sgml : 20221219 20221219194021 ACCESSION NUMBER: 0001209191-22-062044 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20221219 DATE AS OF CHANGE: 20221219 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Thorp Clay CENTRAL INDEX KEY: 0001592380 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-37783 FILM NUMBER: 221472548 MAIL ADDRESS: STREET 1: C/O HATTERAS VENTURE PARTNERS III, LP STREET 2: 280 S. MANGUM ST., SUITE 350 CITY: DURHAM STATE: NC ZIP: 27701 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Clearside Biomedical, Inc. CENTRAL INDEX KEY: 0001539029 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 452437375 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 BUSINESS PHONE: 678-270-3631 MAIL ADDRESS: STREET 1: 900 NORTH POINT PARKWAY STREET 2: SUITE 200 CITY: ALPHARETTA STATE: GA ZIP: 30005 4/A 1 doc4a.xml FORM 4/A SUBMISSION X0306 4/A 2021-02-10 2021-02-10 0 0001539029 Clearside Biomedical, Inc. CLSD 0001592380 Thorp Clay C/O CLEARSIDE BIOMEDICAL, INC. 900 NORTH POINT PARKWAY, SUITE 200 ALPHARETTA GA 30005 1 0 0 0 Common Stock 2021-02-10 4 S 0 32873 4.43 D 4951547 D The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the record holders of the securities on March 16, 2020. Consists of (i) 447 shares sold by Hatteras NC Fund, LP ("Hatteras NC"), (ii) 21,095 shares sold by Hatteras Venture Partners III, LP ("HVP III"), (iii) 1,916 shares sold by Hatteras Venture Affiliates III, LP ("HVA III") and (iv) 9,415 shares sold by Hatteras Venture Partners IV SBIC, LP ("HVP IV SBIC"). This transaction was executed in multiple trades at prices ranging from $4.40 to $4.50, inclusive. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. The original Form 4 inadvertently misstated the total number of shares. This reflect the accurate number of shares beneficially owned. /s/ Mark Ballantyne, Attorney-in-Fact for Clay Thorp 2022-12-19